Recent

% | $
Quotes you view appear here for quick access.

Celldex Therapeutics, Inc. Message Board

  • raysfrom98 raysfrom98 Nov 7, 2013 2:15 PM Flag

    The Wall Street Journal

    Celldex Therapeutics' CDX-1127 Well Tolerated and Demonstrates Anti-Tumor Activity in Phase 1 Dose-Escalation Study

    Very favorable safety profile; no evidence of immune related toxicities

    Three patients with significant tumor shrinkage, including an ongoing CR in Hodgkin disease

    Eight patients with stable disease or better; PFS range of 3.0 to 14+ months

    Immune monitoring data in patients confirms CDX-1127 mechanism of action

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Hitting the WSJ is big!

      Sentiment: Strong Buy

    • The WSJ, Continued

      "CDX-1127 has exceeded our expectations thus far in this ongoing Phase 1 dose-escalation study," said Thomas Davis, MD, Senior Vice President and Chief Medical Officer of Celldex Therapeutics. "Our primary goal was to establish a favorable safety profile, a challenge that other agonist antibodies in this class have not been able to meet. To date, CDX-1127 has demonstrated minimal toxicity and, importantly, no evidence of worrisome overlap with toxicities seen with other immunotherapies--a critical hurdle for combination therapy. We were also very pleased to see clear evidence of biologic and anti-cancer activity in a heavily pretreated patient population. While future data from the expansion cohorts will be important to understanding single-agent activity, we are confident based on the dose-escalation data we have seen to date that we are well positioned to initiate combination studies of CDX-1127, with a particular interest in immune modulators."

      • 1 Reply to raysfrom98
      • WSJ continued

        "A 28 year old female with Stage IV Hodgkin lymphoma achieved a complete
        response, including complete resolution of B symptoms (drenching sweats,
        pruritus and weight loss)--an important marker of disease activity in
        Hodgkin disease, after three cycles of CDX-1127 (0.3 mg/kg). The patient
        remains in remission at 8.6+ months. During treatment, the area of
        measurable lesions first increased and then regressed. This pattern is
        consistent with the current perception of an immune mediated response.
        The patient was heavily pretreated, including high dose chemotherapy with
        autologous marrow transplantation, and most recently had progressed after
        less than one month on Adcetris(TM) plus chemotherapy. "

 
CLDX
23.55+0.03(+0.13%)Jul 31 4:00 PMEDT